
ELAN Stock Forecast & Price Target
ELAN Analyst Ratings
Bulls say
Elanco Animal Health demonstrates strong market positioning with its Simparica Trio maintaining over a 50% market share, indicating robust competitiveness in the companion animal sector. Additionally, the anticipated growth of Credelio Quattro, projected to rise to 16.8% market share by 2026, further underscores the company’s growth trajectory in the animal health market. Furthermore, significant year-over-year sales increases in key product lines, such as the Advantage Family and Seresto, which have recorded 33% and 28% growth respectively, reflect sustained demand and operational momentum.
Bears say
Elanco Animal Health is facing challenges regarding its refinancing strategy, which may pose a near-term risk to earnings growth in 2026, particularly in light of rising interest rates reflected by a recent $550MM offering by Dentsply Sirona at 8.375%. Despite a 50% increase in revenue, the company has experienced a decline in EBITDA margin by a couple of hundred basis points, indicating potential inefficiencies or rising costs that could impact profitability. Additionally, while Elanco reported a $28MM EBITDA outperformance in the second quarter, the overall financial metrics suggest underlying weaknesses that could hinder future growth prospects.
This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ELAN Analyst Forecast & Price Prediction
Start investing in ELAN
Order type
Buy in
Order amount
Est. shares
0 shares